Expert Interview
Discussing novel therapies in Graves' Disease with a focus on batoclimab and IMVT-1401 from Immunovant
Ticker(s): IMVT, ROIVInstitution: University of Michigan
- Clinical Endocrinologist, Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences and Professor, Department of Internal Medicine at the University of Michigan.
- 95% of his patients have Thyroid-Associated Ophthalmopathy (Graves' Orbitopathy)
- Very familiar with the literature to date for teprotumumab and research focuses on Graves' disease, thyroid-associated ophthalmopathy, and metabolic diseases.
How are you currently treating Graves' Disease patients?
Added By: wilson_adminHow optimistic on IMVT-1401 based on the existing data?
Added By: wilson_adminWhat other novel therapeutics for Graves' disease look interesting to you?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
